Published December, 2010
By Kelly K. Hunt, Stephan A. Vorburger and Stephen G. Swisher
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

The three sections of this volume present currently available cancer gene therapy techniques. In Part II, the contributors discuss strategies and targets for the treatment of cancer. Finally, in Part III, experts discuss the difficulties inherent in bringing gene therapy treatment for cancer to the clinic.

---

Published December, 2010
By Mary L. Disis
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Expert bench and clinical scientists join forces to concurrently review both the state-of-the-art in tumor immunology and its clinical translation into promising practical treatments.

---

Published December, 2010
By David A. Gewirtz, Shawn Edan Holt, Steven Grant, Shawn E. Holt and David Gewirtz
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating: 1.00
Availability: Available

This book provides insight into established practices and research into apoptosis and senescence. The volume thoroughly examines novel and emerging techniques and research in the fields of cell death pathways, senescence growth arrest, drugs and resistance, DNA damage response, and other topics that still hold mysteries for researchers.

---

Published December, 2010
By Beverly A. Teicher
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Leading experts summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to anticancer drugs, and suggest new approaches to preventing and overcoming it.

---

Published December, 2010
By Sayed S. Daoud
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

It details current technologies used in proteomics, examines the use proteomics in cell signaling, presents clinical applications of proteomics in cancer therapy, and looks at the role of the FDA in regulating the use of proteomics.

---

Published December, 2010
By Nicholas P. Farrell and Lloyd R. Kelland
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Writing from a variety of disciplines, these authorities discuss the chemistry of cisplatin in aqueous solution, the molecular interaction of platinum drugs with DNA, and such exciting new areas as DNA mismatch repair and replicative bypass, apoptosis, and the transport of platinum drugs into tumor cells.

---

Published December, 2010
By Vinata B. Lokeshwar, Axel S. Merseburger and Stefan H. Hautmann
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Clinical management of bladder cancer is challenging because of the heterogeneity among bladder tumors with respect to invasion and metastasis, frequent occurrence of new tumors in the bladder among patients treated with bladder preservation treatments and poor prognosis of patients with tumors that invade the bladder muscle and beyond.

---

Published December, 2010
By Beverly A. Teicher
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

The past 6 years since the first edition of this book have seen great progress in the development of genetically engineered mouse (GEM) models of cancer.

---

Published December, 2010
By Giampietro Gasparini and Daniel F. Hayes
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators.

---

Published December, 2010
By Doriano Fabbro and Frank McCormick
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Features leading researchers, from the Novartis group who comprehensively survey the developments in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, and more) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer.

---